Clinical trial · people
Thymosin Alpha-1 combo: 47.8% viral response at 24 weeks in hep C
Checked against the paper Clinical trialPublished by PepVault
The takeaway
An early, uncontrolled pilot hints that thymalfasin in a triple combination may help some hepatitis C patients who failed prior therapy, but its own share of the effect remains untested.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 23
- Published
- 2004
- Journal
- J Gastroenterol Hepatol
What they tested
The team tested whether a three-drug combination of thymalfasin, peginterferon alfa-2a and ribavirin could control the virus in people with chronic hepatitis C whose earlier interferon and ribavirin treatment had failed.
How the study was done
A small multicenter pilot trial in which 23 patients with chronic hepatitis C who had not cleared the virus on prior interferon and ribavirin all received the triple combination, with interim results at 24 weeks. There was no comparison group.

What they found
A viral response was seen in 60.8% of patients at week 12 and in 47.8% at week 24. The researchers saw these early results as reason to keep studying the combination.
What it doesn’t show
With only 23 patients and no control arm, the trial can't show how much thymalfasin added beyond peginterferon and ribavirin. These are interim 24-week results from a pilot study, so they don't show whether the response lasted after treatment.
The paper
Poo et al. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J Gastroenterol Hepatol. 2004.
The compound
More studies on Thymosin Alpha-1
- Thymosin alpha-1: lower COVID-19 death risk (RR 0.59) in meta-analysisMeta-analysis · people · 2023
- Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-upMeta-analysis · people · 2008
- Thymosin alpha-1 lowered infections after colorectal cancer surgeryRandomized trial · people · 2024
- Thymosin alpha-1: 3 deaths vs 7 in dialysis COVID-19 pilot so farRandomized trial · people · 2023
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
- Every study on Thymosin Alpha-1
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.